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Anja Weinreich Olsen2 , Jørgen Steen Agerholm1 , Gregers Jungersen3 and  
Peter Andersen2*
1 Section for Veterinary Reproduction and Obstetrics, Department of Large Animal Sciences, Faculty of Health and Medical 
Sciences, University of Copenhagen, Copenhagen, Denmark, 2 Department of Infectious Disease Immunology, Chlamydia 
Vaccine Research, Statens Serum Institut, Copenhagen, Denmark, 3 Section for Immunology and Vaccinology, National 
Veterinary Institute, Technical University of Denmark, Copenhagen, Denmark
International efforts in developing a vaccine against Chlamydia trachomatis have high-
lighted the need for novel immunization strategies for the induction of genital immunity. 
In this study, we evaluated an intramuscular (IM) prime/intranasal boost vaccination 
strategy in a Göttingen Minipig model with a reproductive system very similar to 
humans. The vaccine was composed of C. trachomatis subunit antigens formulated 
in the Th1/Th17 promoting CAF01 adjuvant. IM priming immunizations with CAF01 
induced a significant cell-mediated interferon gamma and interleukin 17A response 
and a significant systemic high-titered neutralizing IgG response. Following genital 
challenge, intranasally boosted groups mounted an accelerated, highly significant 
genital IgA response that correlated with enhanced bacterial clearance on day 3 post 
infection. By detecting antigen-specific secretory component (SC), we showed that the 
genital IgA was locally produced in the genital mucosa. The highly significant inverse 
correlation between the vaginal IgA SC response and the chlamydial load suggests 
that IgA in the minipig model is involved in protection against C. trachomatis. This is 
important both for our understanding of protective immunity and future vaccination 
strategies against C. trachomatis and genital pathogens in general.
Keywords: Chlamydia trachomatis, minipig model, vaccine, vaccination strategy, mucosal vaccination/
immunization, intranasal immunization, mucosal immunity
Abbreviations: CMI, cell-mediated immune; Ct, SvD Chlamydia trachomatis serovar D; DEPC, diethyl dicarbonate; EB, 
elementary body; ELISA, enzyme linked immunosorbent assay; F, forward; IC, internal control; IFN-γ, interferon gamma; 
IFU, inclusion forming unit; IL-17A, interleukin 17A; IM, intramuscular; IN, intranasal; pi, post infection; pIgR, polymeric 
immunoglobulin receptor; R, reverse; SIgA, secretory IgA; SvD, serovar D.
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inTrODUcTiOn
Most of all human infections are established at the mucosal surfaces 
(1), including sexually transmitted infections with Chlamydia 
trachomatis, the most common sexually transmitted bacterium 
globally. C. trachomatis is a major global health problem causing 
more than 100 million new cases of genital chlamydia each year 
(2). Even though the infection can be treated with antibiotics, 
the frequent asymptomatic course of infection, with up to 75% 
symptom-free infections, makes the infection difficult to combat. 
Untreated infections can cause severe permanent complications, 
such as pelvic inflammatory disease, ectopic pregnancy, and 
infertility in women (3).
Screening programs and treatments have been intensified to 
lower the prevalence of C. trachomatis infections, largely without 
the expected impact on the incidence of C. trachomatis cases. 
Therefore, large international efforts are focused on the develop-
ment of a vaccine (3–6).
Chlamydia trachomatis enters the body through the mucosal 
membrane in the genital tract and has a complex lifestyle that 
has been a significant challenge for the design of a vaccine (7). 
Initial bacterial control is most efficiently mediated through 
mucosal neutralizing antibodies (8–11), but interferon gamma 
(IFN-γ) producing Th1 cells becomes pivotal for protection as 
the bacteria infects the epithelial layer and localize intracellularly 
(3, 4, 8). Traditional intramuscular (IM) vaccination strategies 
have recently been implemented against the genital human 
papillomavirus and the correlate for efficacy is specific neutral-
izing systemic IgG (12–14). Whether the same strategy can be 
employed for C. trachomatis is currently unclear but in terms of 
neutralizing antibodies, secretory IgA (SIgA) provide a signifi-
cant theoretical advantage in C. trachomatis immunity due to its 
anti-inflammatory capacity compared to monomeric IgA and 
IgG (15, 16). The hypothetical advantage of anti-inflammatory 
antibodies is to avoid excessive inflammation and thereby 
immune-mediated pathology. Thus, vaccination protocols for the 
induction or redirection of mucosal responses, i.e., SIgA, are the 
subject of intense research (4, 17).
Most mucosal compartments of the body have local mucosal 
immune inductive sites such as gut-associated lymphoid tissue 
and nasal-associated lymphoid tissue. The associated lymphoid 
tissues are responsible for the induction of mucosal immunity 
in the respective mucosal compartments (18, 19). However, as 
the genital tract lacks these immune inductive sites (18, 20), it 
is important to develop an alternative immunization strategy 
that utilizes other mucosal inductive sites to promote local 
genital tract immunity. It has been reported that intranasal 
(IN) immunization can induce mucosal immunity in both 
the respiratory and the genital tracts (1, 21–24). Recently, 
IL-17 secreting CD4+ T-helper cells (Th17 cells) have been 
recognized as a key component in the acceleration of mucosal 
immunity and IgA secretion (25, 26) and studies in mice have 
shown that prime-boost regimes that includes a Th17 prime is 
superior for the induction of mucosal IgA (Christensen et al., 
unpublished).
However, studies in mice can be difficult to translate into 
man as the murine hormonal cycle, reproductive organs, and 
some parameters within the immune system differ significantly 
from humans (27). It is therefore important to verify murine 
concepts in animal models that resemble the human organ sys-
tem of interest. Non-human primates (NHPs) offer the closest 
resemblance of humans, however ethical and practical concerns 
make it difficult to perform experiments in NHPs. Pigs offer a 
great alternative, by having a reproductive cycle, genital tract, 
and immune system that resemble those of humans to a high 
degree (28) and therefore may have better predictive value in 
preclinical evaluation of novel vaccination strategies for genital 
tract immunity.
With the overall aim to develop an immunization protocol for 
the induction of local genital immunity against C. trachomatis, 
we have evaluated the potential of IM prime followed by IN 
boost in the minipig model. We used a multisubunit vaccine with 
recombinant C. trachomatis antigen formulated with CAF01 (29), 
an adjuvant reported to induce a Th1/Th17 response together 
with high antibody titers (8, 30). Our study demonstrates that 
IN boosting in IM/CAF01 primed minipigs induces a striking 
local IgA immune response in the genital tract and an accelerated 
clearance of genital C. trachomatis infection.
MaTerials anD MeThODs
Chlamydia trachomatis
Chlamydia trachomatis serovar D (Ct SvD; UW-3/Cx, ATCC® 
VR-885™), originally isolated from the cervix of a female patient 
with an asymptomatic infection, was grown in HeLa-229 cells, 
harvested, and purified as previously described (31, 32).
Vaccine and adjuvant
Statens Serum Institut (Copenhagen, Denmark) was the provider 
of C. trachomatis vaccine antigen and adjuvant. The minipigs were 
vaccinated with a hybrid vaccine consisting of two recombinant 
C. trachomatis fusion proteins designated Hirep1 (8) and CTH93 
formulated with CAF01 (Cationic Adjuvant Formulation 01) 
adjuvant (29). The Hirep1 subunit is composed of repeated B cell 
epitopes with VD4 regions of MOMP from SvD, SvE, and SvF 
(8). The CTH93 subunit has three T cell epitopes included and 
is composed of CT043 in full length, CT414aa605-804, and MOMP 
SvDaa34-371 (33).
The vaccines for IM administration were composed of 5 μg 
Hirep1 and 5 μg CTH93 (in total 10 μg antigen) in 1  ml Tris 
buffer (10 nM, pH 7.4) mixed with 1 ml CAF01 and sucrose to 
a 9% isotonic solution. The vaccines for IN administration were 
composed of 100 μg Hirep1 and 100 μg CTH93 in 0.5 ml Tris 
buffer and either 0.5 ml 2 × CAF01 (adjuvanted) or 0.5 ml Tris 
buffer (unadjuvanted) plus 9% sucrose.
Minipigs
The study was performed with 24 specific pathogen-free 
(http://minipigs.dk/the-goettingen-minipig/health-status/) 
sexually mature female Göttingen Minipigs (Ellegaard Göttingen 
Minipigs A/S, Dalmose, Denmark). The minipigs were 5–6 
months old at arrival; were housed in isolation units; had 1 week 
of acclimatization before the start of the study; and were under all 
FigUre 1 | experimental setup. Sexually mature Göttingen Minipigs (n = 24) were randomly assigned to four groups with six minipigs in each. The control group 
was given the adjuvant CAF01 intramuscularly two times (2*Adj.). The three vaccinated groups were vaccinated two times intramuscularly (IM) with the vaccine 
composed of Hirep1 and CTH93 with CAF01. One group was not boosted (2*IM), one group was given intranasal (IN) boosters with vaccine antigens alone without 
adjuvant (2*IM/2*IN-Adj.), and the last group was given IN boosters with the complete vaccine including adjuvant (2*IM/2*IN). After the immunizations, the minipigs 
were estrus synchronized and at day 85 all pigs were challenged with 5 × 109C. trachomatis serovar D (Ct SvD) IFUs. Vaginal swabs were collected at days 3, 5, 
and 7 post infection (pi), and they were euthanized at day 15 pi. Abbreviations: Vacc., vaccine (composed of Hirep1 and CTH93 formulated with CAF01); Adj., 
adjuvant (CAF01); IM, intramuscular, IN, intranasal.
December 2015 | Volume 6 | Article 6283
Lorenzen et al. Vaccine Induced Genital Chlamydia Immunity
Frontiers in Immunology | www.frontiersin.org
circumstances treated in accordance with the Danish law on ani-
mal experiments. They were randomly divided into four groups 
with six animals in each (n = 6). The experiment was approved by 
the Danish Animal Experiments Inspectorate (license number: 
2013-15-2934-00978).
immunization
The IM vaccination was performed in the thigh (m. biceps femo-
ris) with a 21-G needle after cleaning the injection area with 70% 
ethanol. The IN vaccination was performed with a nasal delivery 
device (LMA MAD Nasal™, Needle-Free Intranasal Drug 
Delivery, LMA) connected to a 3-ml syringe. The immunization 
protocol for the four groups is illustrated in Figure 1.
experimental challenge infection
Following the immunizations, the minipigs were treated with 
Regumate® (20 mg/minipig/day, orally for 18 days) starting at 
day 62 after the first immunization, to synchronize their estrous 
cycle. They were fed individually in this period, to make sure 
that each minipig had a complete dose each day. Following the 
Regumate® treatment, the minipigs were monitored for estrous 
signs (behavior, hyperemia, and swollenness of the vulva). At the 
time of estrous, the pigs were anesthetized with Zoletil® mixture 
[1 vial Zoletil®50 Vet (125 mg tiletamin and 125 mg zolazepam), 
6.25 ml xylazine (20 mg/ml), 1.25 ml ketamine (100 mg/ml), and 
2.5  ml butorphanol (10  mg/ml)] (34) and inoculated through 
an artificial insemination catheter (Osiris, E-vet, Denmark) 
vaginocervically with 5 × 109C. trachomatis SvD inclusion form-
ing units (IFUs). The bacteria were diluted in 2 ml sterile SPG 
buffer (0.2 M sucrose, 20  mM sodium phosphate, and 5  mM 
glutamic acid buffer). Following the inoculation, the minipigs 
were placed with the hindquarters elevated for 20 min to avoid 
immediate reflux.
sampling and sample Processing
During the immunization period the pigs had their rectal tem-
perature taken 24 and 48 h after each immunization. All animals 
were monitored daily for clinical signs, and after the challenge 
they had their rectal temperature taken daily until day 7 post 
infection (pi) and then again at day 10 pi.
During sampling, the animals were anesthetized by IM injec-
tion with Zoletil® mixture (34) (1 ml/17 kg for vaginal swabbing, 
1  ml/15  kg for blood collection and vaginal swabbing, and 
1 ml/12 kg for inoculation/infection).
Blood samples were collected from v. Jugularis externa at 
the following days after the first immunization: days 0, 14, 
42, 56, 85 (0 pi), 92 (7 pi), and 100 (15 pi) with a vacutainer 
system. Blood samples were collected in coagulation activator-
coated tubes for serum isolation and heparin stabilized tubes 
for isolation of peripheral blood monomuclear cells (PBMCs). 
Blood samples for serum isolation were centrifuged for 15 min 
at 3500 rpm, where after the serum was isolated and stored at 
−20°C.
Vaginal swabs were collected with sterile regular size cotton 
swabs at the following days after the first immunization: days 0, 
14, 42, 56, 85 (0 pi), 88 (3 pi), 90 (5 pi), 92 (7 pi), and 100 (15 pi) 
for determination of mucosal antibody titers and C. trachomatis 
detection. All vaginal swabs were collected in 0.5  ml SPG and 
taken with the help from a vaginoscope, aiming for aseptic 
conditions.
Nasal swabs were taken with sterile minitip cotton swabs. They 
were moistened with sterile SPG and introduced carefully into 
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the nares following the upper-medial border, rolled on the nasal 
mucosa and thereafter stored in 0.5 ml SPG.
The vaginal, genital, and nasal swabs were vortexed for 1 min 
with three sterile glass-beads. The SPG with swab material was 
stored at −80°C until further analyses.
The minipigs were euthanized 15  days pi by IM injection 
of 1 ml/7 kg Zoletil® mixture (34) followed by exsanguination. 
During necropsy, tissue samples and swabs were taken from 
the cervix, uterine body, uterine horns (bilaterally sampled 
both proximally and distally), and the uterine tubes (Fallopian 
tubes). Regular size swabs were used for all swabs except the 
uterine tubes, where minitip size was used. The iliosacral and 
retropharyngeal lymph nodes were collected. The lymph nodes 
were cut into smaller pieces and forced through a metal mesh to 
obtain a homogenized single-cell suspension. They were washed 
twice in RPMI-1640 (Gibco, Invitrogen).
antibody elisa
An indirect enzyme linked immunosorbent assay (ELISA) 
was used to evaluate the antigen-specific antibodies in serum 
and swab samples. Maxisorp® plates (NUNC A/S, Roskilde, 
Denmark) were coated with the vaccine antigens Hirep1 and 
CTH93 (1 μg/ml) over night at 4°C. The isotypes IgG and IgA 
were detected with HRP-conjugated antibodies specific against 
the porcine IgG (Goat anti-pig IgG·Fc, 1:10.000, AAI41P, Serotec, 
UK) and IgA (Goat anti-pig IgA, 1:2000, AAI40P, Serotec, UK). 
The secretory component (SC) was detected with a mouse 
anti-pig Ig SC antibody (MCA634, Serotec, UK) followed by a 
HRP-conjugated goat anti-mouse IgG (H/L) HRP (STAR117P, 
Serotec, UK). The reactions were visualized with TMB PLUS 
substrate (KemEnTec, Taastrup, Denmark) and stopped with 
0.5 M sulfuric acid. The plates were read on an ELISA reader 
at 450  nm with correction at 650  nm. Positive serum from a 
previous study (33) was included as a positive control and two 
wells were run without substrate as a negative control on each 
plate. The positive control was used as an internal standard to 
correct for plate-to-plate variation. The antibody titers were 
calculated as the reciprocal of the highest dilution with an opti-
cal density (OD) value higher than the cutoff. For serum and 
vaginal swab samples, the cutoff was determined from the day 0 
sample mean + 1,745 × SD (35), and in the genital swab samples, 
the cutoff was determined from the negative control (PBS·T·C) 
mean + 1,745 × SD (35).
cytokine expression by PBMc and lymph 
node cells
Peripheral blood monomuclear cells were isolated on a density 
gradient with Lympholyte® Mammal Cedarlane (CL5110, 
TriChem Aps, Skanderborg, Denmark) according to the manu-
facturer’s instructions. PBMC and lymph node cell cultures were 
made in Nunclon round-bottom 96-well plates (NUNC A/S, 
Roskilde, Denmark) with 2 × 105 cell/well in 200 μl RPMI-1640 
supplemented with 5 × 10−5 M 2-mercaptoethanol, 1 mM glu-
tamine, 1% pyruvate, 1% penicillin–streptomycin, 1% HEPES, 
and 10% fetal calf serum (Invitrogen, Taastrup, Denmark). The 
cell cultures were re-stimulated in triplicates with the vaccine 
antigens Hirep1 and CTH93 in 1 μg/ml at 37°C and 5% CO2. 
Stimulation with SEB antigen was used as positive control for 
cell viability, and media was used as negative control. The cell 
culture supernatant was collected after 72  h of incubation and 
stored at −20°C until further analysis. Cytokine concentration in 
the cell culture supernatants was determined by ELISA. IL-17A 
was detected with a rabbit anti-pig IL-17A polyclonal-coating 
antibody (KP0498S-100, Kingfischer Biotech, Saint Paul) (1 μg/
ml) biotinylated rabbit anti-pig IL-17A polyclonal detection 
antibody (KPB0499S-050, Kingfisher Biotech, Saint Paul) in 
0.1  μg/ml and HRP-conjugated streptavidin (SNN1004, Life 
Technologies™, Denmark) in 0.1  μg/ml. IFN-γ was detected 
with a mouse monoclonal anti-pig IFN gamma-coating antibody 
(clone P2F6, Thermo Fisher Scientific, Denmark) 1:550 and a 
biotinylated mouse anti-pig IFN-γ detection antibody (clone 
P2C11, BD Biosciences, Albertslund, Denmark) 1:500 followed 
by HRP-conjugated streptavidin (SNN1004, Invitrogen, Taastrup, 
Denmark) 0.1 μg/ml (36). On each plate, a standard with a known 
concentration of porcine IFN-γ was added in duplicate serial 
dilutions together with two wells without substrate as a negative 
control. A log–log transformed standard curve was made from 
the serial dilutions of the standard, and an equation was made 
correlating the measured OD value with the amount of IFN-γ 
in the sample. This equation was used for determining IFN-γ 
concentration in the samples.
In vitro neutralization assay
An in  vitro neutralization assay using serum from day 85 was 
performed to evaluate the protective capacity of the vaccine-
induced antibodies. The assay principally followed the protocol 
described in (37). The secondary antibody (Alexa Flour 488, 
goat-anti-rabbit IgG, A11008, Life Technologies) was added in the 
dilution 1:500. The evaluation in the fluorescence microscope was 
performed by quantifying the number of inclusions in 20 fields of 
view at 40× magnification (Olympus IX71 inverted microscope). 
Neutralization was calculated as the percentage reduction in the 
number of IFU compared to the sera from control group animals 
(2*Adj.).
qPcr Detection of C. trachomatis on the 
Vaginal Mucosa
DNA extraction from the vaginal swab samples was performed 
with Chelex®100 (Bio-Rad, Life Science, Denmark). The 100 μl 
of the swab material was mixed with 300 μl of a 20% Chelex solu-
tion in TE buffer (T9285, Sigma Aldrich), vortexed for 60 s, and 
incubated at 96°C for 10 min. The sample was then centrifuged 
for 10 min at 17,500 g and 4°C and hereafter triplicates of 5 μl of 
the supernatant was used for PCR.
Real-time qPCR detection of C. trachomatis in the vaginal swab 
samples was performed by detection of the 16S rRNA gene. Internal 
control (IC) and C. trachomatis (Ct) 16s primers were bought from 
TAG Copenhagen A/S (Copenhagen, Denmark) with the fol-
lowing sequence: IC-F 5′ACCGCTCAGGCATTTGCT-3′, IC-R 
5′CCGGGACGTATCATGCT3′, Ct 16s-F GGATCTTCGGACCT 
TTCGGT, Ct 16s-R AATCTCTCAATCCGCCTAGACA. The 
probes were bought from Applied Biosystems (Life Technologies 
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Europe BV, Naerum, Denmark) with the following sequence: Ct 
16s-probe FAM-AAGGGAGAGTCTATGTGATAT – MGBNFQ 
and IC-probe NED-TCCTTCGTGATATCGGACGTTGGCTG –  
MGBNFQ.
The assay was performed with a final reaction volume of 25 μl 
with Perfecta qPCR SuperMix [UNG, low ROX, 95066-02K (2000 
rx) Quantum Biosciences, Gaithersburg, MD, USA], 300  nM 
of each primer; Ct 16s-F, Ct 16s-R, IC-F, and IC-R and 75 nM 
of each of the Ct 16s-probe and IC-probe, IC-DNA and DEPC 
treated water was added up to a total volume of 20 μl. MicroAmp 
Fast 96-well plates (Applied Biosystems, Naerum, Denmark) 
were used with an adhesive cover (MicroAmp Optical Adhesive 
film, Applied Biosystems, Denmark).
The samples were run on a StepOne™ Real-time PCR instru-
ment (Applied Biosystems®), and the instrument was programed 
to run 2 min at 95°C and 40 cycles of denaturation at 95°C for 15 s 
and annealing/extension at 60°C for 1 min. Based on the negative 
control, the Ct cutoff was determined to be 36, hence Ct values 
>36 were considered as nonsense.
statistical analysis
Enzyme linked immunosorbent assay results were normal-
ized according to the IC on each plate. Gaussian distribution 
of all data was analyzed by D'Agostino and Pearson omnibus 
normality test in Graph Pad Prism 5 (GraphPad Software 
Inc., CA, USA). All statistics were performed with GraphPad 
Prism. The not-normally distributed data were if possible log 
transformed and analyzed with one-way ANOVA followed by 
Bonferroni corrected multiple comparisons. If log transforma-
tion was not possible, they were analyzed with non-parametric 
tests; Kruskal–Wallis test and Dunns multiple comparison test. 
Analysis of correlation was performed with Spearman’s rank 
correlation coefficient. The group wise results are presented with 
mean ± SEM errorbars (38). The comparisons were considered 
statistical significant if the P value was <0.05 (P < 0.05). Further 
levels of significance are indicated with asterisks *P  <  0.05, 
**P < 0.01, ***P < 0.001.
resUlTs
experimental Design
To evaluate the effect of a combined vaccination strategy based 
on systemic priming and mucosal boosting, groups of Göttingen 
Minipigs were immunized using different IM prime/IN boost 
regimes and subsequently given a vaginocervical Ct SvD infection. 
The vaccine was a cocktail of two recently developed recombinant 
vaccine fusion proteins, Hirep1 and CTH93 (8, 33) formulated 
with the CAF01 adjuvant promoting both cell-mediated immune 
(CMI) and humoral immune responses (29). Three groups of 
minipigs were vaccinated and compared to a control group receiv-
ing CAF01 adjuvant two times IM (2*Adj.). All three vaccinated 
groups received two IM vaccinations; either alone (2*IM), boosted 
with two IN vaccinations (2*IM/2*IN), or boosted IN with pro-
teins alone without adjuvant (2*IM/2*IN-Adj.) (Figure 1). Blood 
and vaginal swab samples were collected and humoral as well as 
CMI responses were evaluated before and after challenge infection 
together with the vaginal C. trachomatis load pi.
systemic and Mucosal antibody 
responses Post Vaccination
The level and kinetics of the antibody responses specific for 
the two vaccine antigens Hirep1 and CTH93 were evaluated in 
serum and locally on the genital mucosa by ELISA. All vaccinated 
animals had rapidly increasing titers against both Hirep1 and 
CTH93 reaching a significant level at day 14 and a stable plateau 
from days 40 to 85 after the first immunization (Figure 2). Hirep1 
and CTH93 promoted equal antibody levels with almost identical 
kinetics (Figure 2).
Following vaccinations, highly significant serum IgG titers 
were detected in all vaccinated groups (Figure 3), which also led 
to slightly increased vaginal IgG titers (Figure 3). We detected 
no difference in serum IgA levels, but in the vaginal samples, we 
found an increased IgA titer in the group receiving un-adjuvanted 
IN booster immunizations (Figure 3). In addition, a significant 
IgA response was found on the nasal mucosa in both IN-boosted 
groups (mean Hirep1-specific nasal IgA titer: 2*Adj.: 1.7, 2*IM: 
18.3, 2*IM/2*IN-Adj.: 18630***, 2*IM/2*IN: 4560*, Dunn’s mul-
tiple comparison with the 2*Adj. group).
The vaccine-induced serum antibodies were further evaluated 
in an in vitro neutralization assay. Sera from all three vaccinated 
groups showed significant neutralization of C. trachomatis SvD 
compared to the 2*Adj. serum (Figure  4). Furthermore, at a 
serum dilution of 1:16, the two IN-boosted groups showed a sig-
nificantly higher neutralization than the 2*IM immunized group 
(Figure 4, 2*IM/2*IN-Adj.: P < 0.05, 2*IM/2*IN: P < 0.01).
cell-Mediated immune response Post 
Vaccination
In order to characterize the vaccine-induced CMI response, the 
secretion of IFN-γ and interleukin 17A (IL-17A) was evaluated in 
the supernatants of PBMCs re-stimulated with vaccine antigens, 
Hirep1 and CTH93.
All three vaccinated groups raised powerful T cell responses 
measured by secreted IFN-γ to both vaccine components (Hirep1 
and CTH93) with very similar kinetics (Figure 5). The kinetics of 
the IFN-γ response showed a different pattern in the IN-boosted 
groups compared to the 2*IM group, with the IN-boosted 
groups showing a decrease in IFN-γ level after the first IN 
booster (day 56) (Figure 5). All three vaccinated groups raised 
a low but significant Hirep1 PBMC IL-17A response at day 85 
(2*IM: 141.6 pg/ml****, 2*IM/2*IN – Adj.: 91.9 pg/ml****, and 
2*IM/2*IN: 76.5 pg/ml**** compared to the 2*Adj.:3.27 pg/ml).
immune response Post challenge
The vaccinated minipigs were infected with C. trachomatis SvD 
at day 85 after the first immunization. The inoculation was per-
formed during estrus, and the local as well as the systemic humoral 
responses were followed for 15  days pi. The two IN-boosted 
groups showed a significant vaginal IgA response from day 5 pi 
and for the rest of the study period (Figure 6). The vaginal IgA 
titer peaked between day 7 and 15 pi and reached very significant 
levels (titer >10,000) in the IN-boosted group with protein alone 
as well as in the IN-boosted group with the adjuvanted vaccine 
(Figure 6).
FigUre 3 | hirep1-specific antibody responses in serum and on the vaginal mucosa following the immunizations with hirep1 and cTh93 as 
described in Figure 1. Serum and vaginal swabs from day 85 after the first immunization were assayed for antigen-specific IgG and IgA responses by ELISA. (a) 
Hirep1-specific IgG in serum and vagina. (B) Hirep1 specific IgA in serum and vagina. The response against CTH93 was almost identical and therefore not shown. 
Bars show mean ± SEM. Statistics: Dunn’s multiple comparisons. Asterisks (*) indicate significance compared to the 2*Adj. group.
FigUre 2 | The kinetics of antigen-specific igg in serum of vaccinated minipigs. Serum was collected at various timepoints during the immunization period 
and evaluated for Hirep1- and CTH93-specific IgG responses by ELISA. Graphs show mean ± SEM. The black arrows indicate the two IM immunizations and the 
two gray arrows indicate the two IN immunizations.
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FigUre 4 | In vitro serum neutralization after the immunization period. Serum from day 85 after the first immunization and C. trachomatis SvD EBs were 
incubated with HaK cells and the ability of serum antibodies from vaccinated minipigs to inhibit in vitro chlamydial infection of cells, relative to serum from the 2*Adj. 
control group, was evaluated. Percent neutralization is given for each group at the three dilutions of serum. Graph shows mean ± SEM. Statistics: Dunn’s multiple 
comparisons. Asterisks indicate significance compared to the 2*Adj. group.
FigUre 5 | cell-mediated iFn-γ response during the immunization period. The groups of minipigs were immunized according to Figure 1 with Hirep1 and 
CTH93, and the cell-mediated immune response was evaluated during the immunization period by isolating PBMCs, re-stimulating them with Hirep1, CTH93, and 
media whereafter the IFN-γ levels were determined in the supernatant. Graphs show mean ± SEM. The black arrows indicate the two IM immunizations and the two 
gray arrows indicate the two IN immunizations.
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At the necropsy (day 15 pi), swab samples were collected from 
all compartments of the genital tract to evaluate the presence of 
antibodies on the genital mucosa. We found significant levels of 
specific IgA in both the cervix and the upper genital tract (uterine 
body and horns) in the IN-boosted groups (Figure 7A). Although 
not statistically significant, we also found an IgA response in 
FigUre 6 | Vaginal hirep1-specific iga response following vaginal challenge. After the immunization protocol (Figure 1), the minipigs were challenged 
vaginally with C. trachomatis SvD and vaginal swabs were collected and assayed for Hirep1- and CTH93-specific IgA by ELISA. The response against CTH93 was 
almost identical and therefore not shown. Graphs show mean ± SEM. Statistics: Dunn’s multiple comparisons. Symbol (a) indicates significance compared to the 
2*Adj. group and (b) indicates significance compared to the 2*IM group. Asterisks indicate significance level.
FigUre 7 | hirep1-specific iga antibody responses in the genital tract on day 15 pi. Following the immunizations as illustrated in Figure 1, minipigs were 
challenged vaginally with C. trachomatis SvD and 15 days pi, the minipigs were euthanized and swabs from the cervix, the uterine body and horns (upper) and 
uterine tubes were evaluated for Hirep1-specific IgA. (a) The definition of the three locations in the genital tract: the cervix, the upper genital tract including swabs 
from the uterine body and horns, and then the uterine tubes (Fallopian tubes) (B) The IgA titers in the four groups. Bars show mean ± SEM. Statistics: Dunn’s 
multiple comparisons. Symbol (a) indicates significance compared to the 2*Adj. group and (b) indicates significance compared to the 2*IM group. Asterisks indicate 
significance level (**P < 0.01 and ****P < 0.0001).
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the uterine tubes in the 2*IM/2*IN-Adj. group (Figure  7A). 
Furthermore, vaginal IgG titers were significantly increased 
throughout the genital tract at day 15 pi in all three vaccinated 
groups (data not shown).
Enzyme linked immunosorbent assay detection of SC on 
the vaginal mucosa was performed to investigate the level 
of locally produced IgA. The IN-boosted groups showed a 
significant Hirep1 specific SC titer on day 15 pi (Figure  8A). 
The minipigs vaccinated only 2*IM did not have increased SC 
titers (Figure 8A). When comparing the vaginal IgA titers with 
the vaginal SC titers on day 15 pi, we found a significant cor-
relation between the IgA and SC response against both vaccine 
antigens (Spearman’s correlation test; Hirep1: r =  0.59** and 
CTH93: r = 0.49*).
FigUre 8 | secretory component and chlamydial load on the vaginal mucosa following genital challenge. (a) Hirep1-specific secretory component (SC) 
detected by ELISA in vaginal swabs on day 15 pi. Bars show mean ± SEM. (B) Vaginal Chlamydia load on day 3 pi detected by 16s qPCR in vaginal swabs. Each 
dot represents the mean of triplicates. A value of 0 on the y axis corresponds to a non-detectable value. Horizontal line represents median. Statistics: Dunn’s 
multiple comparison tests. Symbol (a) indicates significance compared to the 2*Adj. group and (b) indicates significance compared to the 2*IM group. Asterisks 
indicate significance level.
TaBle 1 | lymph node iFn-γ and il-17a response to hirep1 
re-stimulation at day 15 pi.
iFn-γ (ng/ml) il-17a (pg/ml)
2*Adj. 0.15 ± 0.05  1.5 ± 0.74 
2*IM 0.67 ± 0.20 20.9 ± 5.80**
2*IM/2*IN-Adj. 1.81 ± 0.66** 39.1 ± 10.7***
2*IM/2*IN 1.20 ± 0.43 69.3 ± 36.2
Data: mean ± SEM. Asterisks indicate significance level when compared to the 
2*Adj. control group. Statistics: Bonferroni corrected multiple comparisons on log 
transformed data.
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Evaluation of CMI responses at day 15 pi was performed by 
measuring the IFN-γ and IL-17A levels in the supernatants of 
lymph node cells (Lnn. Iliosacrales) re-stimulated with Hirep1. All 
three vaccinated groups showed an IFN-γ and IL-17A response in 
the iliosacral lymph node compared to the response in the 2*Adj. 
control group, although not all responses reached significant 
levels due to individual variation and the relatively small group 
sizes (Table 1).
Vaginal C. trachomatis load Post infection
Protective efficacy was evaluated by the vaginal chlamydial load 
after challenge infection. Vaginal swabs were taken at days 3, 5, 
7, and 15 pi, and the level of chlamydial 16S DNA was evaluated 
by q-PCR. All pigs rapidly cleared the infection and vaccine-
promoted protection could only be observed at day 3 pi, where 
the levels of chlamydial DNA were significantly (10-100-fold) 
decreased in the two IN-boosted groups of pigs compared to the 
2*Adj. control group and the 2*IM immunized pigs (Figure 8B). 
There was a highly significant inverse correlation between the 
vaginal chlamydial load on day 3 pi and the vaginal Hirep1 specific 
IgA on day 5 pi (Spearman’s r = −0.64***), day 7 pi (Spearman’s 
r  =  −0.71***), and day 15 pi (Spearman’s r  =  −0.67***). 
Furthermore, there was a highly significant inverse correlation 
between the chlamydial load on day 3 pi and the levels of SC on 
day 15 pi (Spearman’s r = −0.71****).
DiscUssiOn
It is becoming increasingly clear that mucosal IgA and IgG 
antibodies represent an important part of the protective immune 
response against genital C. trachomatis infection (8, 10, 11, 39, 
40). In the current study, we demonstrate that an immunization 
strategy with IM priming and IN boosting, results in a strong 
significant SIgA response in the genital tract of female minipigs 
following genital challenge and furthermore that the local SIgA 
response appears to be important for an accelerated clearance of 
a genital C. trachomatis infection.
Our findings are relevant in the ongoing debate on the 
importance of antibodies in the protection against C. trachomatis 
infection and pathology (8, 10, 39, 41). IgA has recently attracted 
significant attention as an important part of the protective immu-
nity against C. trachomatis (10, 40), and SIgA may be of particular 
relevance to protection against C. trachomatis due to its neutral-
izing and anti-inflammatory capacities, compared to monomeric 
IgA and IgG (16). IgA produced by local plasma cells in the 
genital mucosa will predominantly be of the polymeric forms 
and therefore be attached to the SC, when transported across the 
genital epithelium via the polymeric immunoglobulin receptor 
(pIgR) (16, 18, 20, 42, 43). Hence, the SC we detected on the vagi-
nal mucosa will most likely represent locally produced IgA. We 
cannot rule out that the small amounts of serum polymeric IgA 
(pIgA) could be transported across the epithelium with the pIgR, 
and therefore attached to SC. However, since we did not detect 
any specific IgA response in serum in the IN-boosted groups, our 
data suggest that the vaginal pIgA is locally produced. Whether 
IgA-committed B cells are found in the genital tract already after 
IN immunizations and just need to be activated in the presence of 
antigen during infection, or whether IgA-committed B cells needs 
to migrate into the genital tract mucosa after challenge infection 
is currently unknown.
Earlier vaccine trials in pigs, with IN vaccination, have not 
shown a mucosal immune response in the genital tract (44) 
and it has never been experimentally addressed whether the 
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nasal–genital immunization route exists in pigs. The significant 
genital IgA response after infection in the IN-boosted groups, 
in this study, confirms that the nasal–genital bridge does exist 
in pigs and our data thereby demonstrate the importance of a 
prime-boost strategy for the induction of local genital IgA. Our 
findings are in agreement with recent studies in mice, showing 
that parental priming followed by mucosal boosting efficiently 
recruits CD4 T cells to the mucosa and facilitates IgA secretion 
(1, 45). Our study is the first demonstration of vaccine-promoted 
IgA in the female genital tract in a more human-relevant porcine 
model, confirming the findings from mice that IN booster immu-
nizations can induce genital IgA (1).
IN-boosted pigs were significantly protected at day 3 pi 
compared to the IM vaccinated and whereas these immuniza-
tion strategies promoted identical serum IgG levels they clearly 
differed in local vaginal IgA levels. The highly significant inverse 
correlation between the vaginal IgA SC response and the 
chlamydial load therefore suggest that IgA in the minipig model 
is involved in protection against C. trachomatis. It is however 
important to emphasize that our data do not exclude a role for 
IgG in protection against C. trachomatis. Another recent study 
in the minipig model with the same vaccine antigen suggests that 
IM vaccination (without mucosal boost), can confer protection 
even without IgA, if the IgG titers are sufficiently high (33). Thus 
both vaginal IgG and IgA seem to have protective potential in the 
porcine model.
In the present study, the infection was rapidly eliminated, and 
no difference in vaginal chlamydial load was detected beyond day 
3 pi, which limits the ability of this model for the study of, e.g., 
the influence of Th1 cells on the more chronic stages of infec-
tion. The reason for this fast clearance may be related to, i.e., the 
inoculation during estrus as reported for other pathogens (46); a 
possibility that we are currently investigating (data not shown).
The CAF01 adjuvant used in this study signals through the 
CLEC receptor Mincle and induces a Th1/Th17 response together 
with high antibody titers in mice (29, 47). In this study, we show 
that the IM immunizations with the CAF01 adjuvanted vaccine 
induce high titers of neutralizing IgG and a Th1/Th17 response 
in pigs. The Th1/Th17 profile of this adjuvant may be a very good 
match for a C. trachomatis vaccine. IFN-γ (Th1) is generally 
accepted as a key cytokine for protection against C. trachoma-
tis and activates a number of important effector pathways of 
relevance for elimination of the intracellular bacteria (41, 48). 
Th17 cells on the other hand, have the potential to transform 
into follicular helper T (Tfh) cells with the ability to induce 
IgA-isotype switched B cells (26) and recently it was shown that 
IL-17 is necessary for the induction of IgA in the airway mucosa 
(Christensen et al., unpublished). Furthermore, IL-17 facilitates B 
cell recruitment and upregulation of the pIgR in the airways (25).
Our study compared IN boost with or without adjuvant and 
found similar significant levels of nasal and genital IgA in both 
of the IN-boosted groups, suggesting that in minipigs primed 
by a CAF01 adjuvanted vaccine, the presence of adjuvant in the 
boost may not be critically important. Thus although CAF01 has 
been described to function as a mucosal adjuvant (49), its effect 
on IgA induction when administered as a mucosal booster on 
top of a strong systemic response is limited. Whether this lack 
of an additive value of mucosal adjuvant in Th1/Th17 primed 
animals is a general phenomenon is not clear. It is likely that 
using stronger experimental mucosal adjuvants like cholera 
toxin could improve the effect of nasal boosting even further also 
in primed animals.
For the purpose of human trials and safety issues regarding IN 
administration of vaccines, it is promising that the antigen alone 
is capable of inducing a mucosal immune response similar to the 
IN vaccine with CAF01.
In conclusion, our data show that IN booster immunizations 
can induce a significant SIgA response in the genital tract of 
female minipigs and suggest that this response is involved in 
the accelerated clearance of a genital C. trachomatis infection. 
This information is important both for our understanding of 
protective immunity and future vaccine strategies against this 
important pathogen.
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